Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, Bohnenberger H, Knödler M, Kurreck A, Sulzer S, Beyer G, Dorman K, Fröhlich T, Hegenberg S, Lugnier C, Saborowski A, Vogel A, Lange S, Reichert M, Flade F, Klaas L, Utpatel K, Becker H, Bleckmann A, Wethmar K, Reinacher-Schick A, Westphalen CB. Witte D, et al. Among authors: westphalen cb. J Cancer Res Clin Oncol. 2024 Oct 1;150(10):438. doi: 10.1007/s00432-024-05954-5. J Cancer Res Clin Oncol. 2024. PMID: 39352477 Free PMC article.
Targeted RT study: results on early toxicity of targeted therapies and radiotherapy.
Konnerth D, Gaasch A, Westphalen CB, Heinrich K, Niyazi M, Eze C, Rogowski P, Marschner S, Zinn A, Belka C, Corradini S, Schönecker S. Konnerth D, et al. Among authors: westphalen cb. Radiat Oncol. 2024 Aug 29;19(1):113. doi: 10.1186/s13014-024-02494-7. Radiat Oncol. 2024. PMID: 39210363 Free PMC article.
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, Halabi S, Michiels S, Yap C, André F, Bibeau F, Curigliano G, Garralda E, Kummar S, Kurzrock R, Limaye S, Loges S, Marabelle A, Marchió C, Mateo J, Rodon J, Spanic T, Pentheroudakis G, Subbiah V. Westphalen CB, et al. Ann Oncol. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25. Ann Oncol. 2024. PMID: 39187421 Free article.
ESMO Recommendations on clinical reporting of genomic test results for solid cancers.
van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. van de Haar J, et al. Among authors: westphalen cb. Ann Oncol. 2024 Nov;35(11):954-967. doi: 10.1016/j.annonc.2024.06.018. Epub 2024 Jul 9. Ann Oncol. 2024. PMID: 39112111 Free article.
Correction: Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, Bergwelt-Baildon MV, Ricke J, Heinemann V, Westphalen CB, Kunz WG. Mansour N, et al. Among authors: westphalen cb. Cancer Imaging. 2024 Jul 1;24(1):82. doi: 10.1186/s40644-024-00724-5. Cancer Imaging. 2024. PMID: 38951928 Free PMC article. No abstract available.
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, von Bergwelt-Baildon M, Ricke J, Heinemann V, Westphalen CB, Kunz WG. Mansour N, et al. Among authors: westphalen cb. Cancer Imaging. 2024 Jun 7;24(1):70. doi: 10.1186/s40644-024-00708-5. Cancer Imaging. 2024. PMID: 38849902 Free PMC article.
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, Bonastre J, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F. Mosele MF, et al. Among authors: westphalen cb. Ann Oncol. 2024 Jul;35(7):588-606. doi: 10.1016/j.annonc.2024.04.005. Epub 2024 May 27. Ann Oncol. 2024. PMID: 38834388 Free article.
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Ambrosini M, et al. Among authors: westphalen cb. Ann Oncol. 2024 Jul;35(7):643-655. doi: 10.1016/j.annonc.2024.03.009. Epub 2024 May 22. Ann Oncol. 2024. PMID: 38777726 Free article.
What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.
Pretzell I, Desuki A, Bleckmann A, Loges S, Reinacher-Schick A, Westphalen CB, Lange S; TEAM-D Participants. Pretzell I, et al. Among authors: westphalen cb. Oncol Res Treat. 2024;47(9):410-419. doi: 10.1159/000539217. Epub 2024 May 7. Oncol Res Treat. 2024. PMID: 38714183
142 results